Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults

Last updated: December 2, 2024
Sponsor: SF Research Institute, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphocytic Leukemia, Acute

Treatment

KSM-66 Ashwagandha Root Extract

Clinical Study ID

NCT06244147
Ixoreal-Safety-CT-06-22
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The primary objective is to evaluate the clinical safety of KSM-66 Ashwagandha (Withania Somnifera) on long-term administration over 12 months. The secondary objectives are to evaluate the laboratory safety of KSM-66 Ashwagandha (Withania Somnifera) on long-term administration over 12 months and to evaluate the efficacy of KSM-66 Ashwagandha (Withania Somnifera) on long-term administration over 12 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults (male and female) aged between 18 and 65 years.

  • Prescribed KSM-66 Ashwagandha by their clinicians for long-term period.

  • No plan to commence any other alternative treatment modality for their conditions.

  • Willingness to sign an informed consent document and to comply with all studyrelated procedures.

  • Participants with Body mass index between 25 and 39.9 kg/m2.

Exclusion

Exclusion Criteria:

  • Patients receiving any of the medications known to affect stress and anxiety (corticosteroids, antidepressants, anti-psychotics, mood stabilizers, andanti-epileptic medications) during 4 weeks prior to screening.

  • Patients currently (or within the past 4 weeks prior to screening) taking any overthe counter use of herbal extracts such as Ginkgo Biloba, St. John's Wort, Omega-3etc.

  • Patients with depressive episode, suicidal tendency, panic disorder, social phobia,obsessive-compulsory disorder; alcohol dependency; schizophrenia and mania.

  • Patients with known post-traumatic stress disorder (PTSD).

  • Patients with known clinically significant acute unstable hepatic, renal,cardiovascular, or respiratory disease that will prevent participation in the study.

  • Patients with known hypersensitivity to Ashwagandha.

  • Patients who had participated in other clinical trials during previous 3 months.

  • Patients who have any clinical condition, according to the investigator which doesnot allow safe fulfillment of clinical trial protocol.

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: KSM-66 Ashwagandha Root Extract
Phase:
Study Start date:
February 15, 2024
Estimated Completion Date:
February 28, 2025

Study Description

To qualify for this study, participant must be male or female between 18 and 65 years old and prescribed KSM-66 Ashwagandha by their clinicians for a long-term period. Participants must have no plan to commence any other alternative treatment modality for their conditions. Participants must be willing to sign an informed consent document and to comply with all study related procedures. Participants must have a body mass index between 25 and 39.9 kg/m2.

In this study, a total of 200 subjects will be included across 4-5 study sites, for a total duration of 12 months. At the initial visit, prospective patients will be screened for enrollment based on the requirements of the study, medical history, and clinical examination. Before starting any study related procedures, participants will be explained about the study in detail and a written informed consent will be obtained from participants prior to participation in this study. This document is a part of the written informed consent procedure. A detailed medical history including the associated conditions will be recorded. A general and physical examination will be performed to detect any abnormal parameters. If participants meet the eligibility criteria, they will be enrolled in the study.

After enrollment in the study, participants will be asked to consume Ashwagandha 300 mg root extract capsule orally twice daily, morning and evening after breakfast and dinner with a glass of water. At Visit 1 (Screening/Enrollment/Baseline Visit - Day -3 to Day 0), demography and medical history will be taken, physical examination and vital signs will be performed, blood will be collected, study medication will be dispensed, and Clinical Global Impression - Improvement (CGI-I) scale and Quality of Life using the SF-12 QoL scale will be assessed.

At Visits 2 to 6 (Months 1, 2, 3, 4, 5), participants will follow up remotely via a phone call. Compliance and concomitant medication will be noted.

At Visit 7 (Month 7), participants will follow up on site, where a physical examination and vital signs will be performed, blood will be collected, study medication will be dispensed, Clinical Global Impression - Improvement (CGI-I) scale and Quality of Life using the SF-12 QoL scale will be assessed, and compliance will be assessed.

At Visits 8 to 12 (Months 7, 8, 9, 10, 11), participants will follow up remotely via a phone call. Compliance and concomitant medication will be noted.

At Visit 13 (Final Visit - Month 12), participants will follow up on site, where a physical examination and vital signs will be performed, blood will be collected, Clinical Global Impression - Improvement (CGI-I) scale and Quality of Life using the SF-12 QoL scale will be assessed, and compliance will be assessed. Participants will be monitored throughout the study, including any adverse events.

Connect with a study center

  • SF Research Institute

    San Francisco, California 94127
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.